PregLem SA

Quick facts

Phase 3 pipeline

• PGL4001 · Gynecology / Women's Health
  PGL4001 is a selective progesterone receptor modulator that acts as a progesterone agonist to reduce uterine contractions and bleeding.
• PGL4001 matching placebo and iron · Obstetrics/Gynecology
  PGL4001 is a selective progesterone receptor agonist that promotes endometrial decidualization and suppresses uterine contractions to prevent miscarriage.
• PGL4001, placebo, drug free period · Obstetrics / Women's Health
  PGL4001 is a selective progesterone receptor agonist that promotes uterine quiescence and prevents preterm labor.
• PGL4001, progestin · Gynecology / Women's Health
  PGL4001 is a selective progesterone receptor agonist that mimics the action of the natural hormone progesterone to modulate uterine contractility and endometrial function.
• PGL4001, progestin, drug free period · Contraception / Women's Health
  PGL4001 is a selective progesterone receptor modulator that provides contraceptive and menstrual regulation effects through progestin activity with a structured drug-free period.
• PGL4001 (ulipristal) and iron · Gynecology / Women's Health
  Ulipristal is a selective progesterone receptor modulator that suppresses ovulation and alters the endometrium, while iron supplementation addresses iron deficiency anemia.
• Ulipristal Acetate - open label · Reproductive health
  Ulipristal acetate is a selective progesterone receptor modulator that acts as an antagonist to progesterone.

Phase 2 pipeline

• PGL5001

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PregLem SA portfolio CI brief
• PregLem SA pipeline updates RSS